A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots,
also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can
occasionally be life-threatening. The purpose of this study is to determine if a daily
injection of a blood-thinner, dalteparin, for 12 weeks can safely and effectively reduce the
frequency of blood clots. Dalteparin is currently approved for prevention of blood clots
following surgery and in hospitalized patients but not specifically for cancer outpatients.
Phase:
Phase 3
Details
Lead Sponsor:
University of Rochester
Collaborators:
Eisai Inc. National Heart, Lung, and Blood Institute (NHLBI)